Adaptive Biotechnologies Corporation (ADPT) — Fundamental Analysis

Snapshot & Big Picture

Adaptive Biotechnologies is a Seattle-based commercial-stage biotechnology company best known for its immune medicine platform. The company operates two primary revenue-generating segments: MRD (Minimal Residual Disease) testing under the clonoSEQ brand — the first FDA-cleared test for detecting residual cancer in blood malignancies — and its broader immune medicine research services. Over the years, Adaptive has been building a business around decoding the adaptive immune system to diagnose and treat disease.

From a high level, ADPT is a growth-stage biotech that has consistently operated at a loss since its 2019 IPO. The headline story entering 2025 is a dramatic acceleration in revenue alongside a significant narrowing of losses — suggesting the business may be approaching an inflection point, even if profitability remains a future goal rather than a present reality.

Latest Quarter Snapshot (Q1 2026 — Most Recent Available)

The most recent data comes from the 10-Q filed on May 5, 2026, covering the quarter ended March 31, 2026. This is more current than the annual figures and offers the freshest read on business momentum.

At $70.9 million in quarterly revenue, ADPT is running at an annualized pace of roughly $284 million, which would represent a continuation of the strong growth seen in fiscal year 2025. Losses remain but are materially smaller than prior years on a margin basis. The operating margin of -27.1% is far improved from earlier periods and consistent with the full-year 2025 trend.

Profitability — Multi-Year Trend

ADPT has never been profitable, but the trajectory of its losses has improved meaningfully. The table below tracks operating and net margins from the annual 10-K filings.

The 2023 year stands out as a trough — revenue actually declined slightly from 2022 while EBITDA losses deepened to -$207 million. Since then, the recovery has been sharp. Fiscal 2025 saw revenue surge to $277 million (a ~55% jump from 2024) while EBITDA losses compressed dramatically to -$41 million. The operating margin improved from -90.8% in 2024 to -20.6% in 2025 — the best figure in the company's reported history. Gross margin data was not available in the filed data for any period.

The 2020–2021 period of deepening losses coincides with heavy investment in the company's (now discontinued or restructured) partnership with Genentech/Roche on immune-driven drug discovery, which ultimately did not pan out at scale. The subsequent refocus on clonoSEQ MRD testing appears to be driving the current improvement.

Financial Health

Liquidity has been a relative strength for ADPT throughout its history. The current ratio — a measure of short-term assets versus short-term liabilities — has remained comfortably above 1.0x in every reported period, reflecting the capital raised during its IPO and subsequent equity offerings.

Debt-to-equity figures were not available in the filings for fiscal years 2017–2021, likely reflecting minimal formal debt in those periods (the company was largely equity-financed post-IPO). From 2022 onward, D/E has crept up modestly but remains below 0.7x, which is manageable. The current ratio has declined from the lofty 6–8x range seen when the company held large post-IPO cash piles, but at 3.3–3.4x in recent quarters, near-term liquidity appears adequate.

Capital expenditures tell a particularly interesting story. CapEx surged to $61.7 million in 2021 (40% of revenue) — likely tied to laboratory infrastructure and facility buildout — then collapsed sharply. By 2024 and 2025, CapEx had fallen to $3.7 million and $3.0 million respectively (under 2% of revenue), and Q1 2026 shows a continuation of that trend at $0.8 million. This dramatic decline in capital intensity suggests the heavy infrastructure investment phase is largely behind ADPT and that the current revenue growth is being achieved with minimal incremental fixed-asset investment — a positive signal for eventual free cash flow generation as losses continue to narrow.

Growth

Revenue growth has been the company's most consistent positive fundamental. Below are the pre-calculated trailing CAGRs based on annual 10-K filings:

The 5-year CAGR of 23.0% reflects strong underlying growth momentum across the full period, while the 3-year CAGR of 14.3% — though lower — is somewhat understated by the weak 2023 revenue year. Given that fiscal 2025 saw a ~55% surge in revenue versus 2024, the forward-looking pace of growth may be considerably higher than either trailing CAGR implies, contingent on continued clonoSEQ adoption and any new revenue streams materializing.

Plain English Summary

Adaptive Biotechnologies has been losing money since it went public, but the story in 2025 changed meaningfully. Revenue jumped roughly 55% in a single year to $277 million, while operating losses shrank to their smallest level in the company's public history at just 20 cents per dollar of revenue — compared to 90 cents the year before. The company is still in the red, but the trajectory has clearly turned. Capital spending has fallen off a cliff from a $61 million peak in 2021 down to under $3 million annually, which means revenue growth is no longer requiring heavy reinvestment in physical infrastructure — a good sign for the path to cash-flow breakeven. The balance sheet remains reasonably healthy with a current ratio above 3x and manageable debt levels. The 10-year CAGR isn't calculable given ADPT's filing history, but the 5-year CAGR of 23% and the acceleration evident in 2025 paint a picture of a company that has narrowed its focus (primarily on its FDA-cleared clonoSEQ MRD testing product) and is beginning to benefit from that discipline. Whether ADPT can cross into profitability — or at least sustainable cash-flow breakeven — remains the central investment question, but 2025 and early 2026 data suggest it is closer than it has ever been.

Source Filings

• 10-Q filed May 5, 2026 — Quarter ended March 31, 2026
• 10-K filed February 26, 2026 — Fiscal Year ended December 31, 2025